Laura Dean
About
In The Last Decade
Laura Dean
50 papers receiving 630 citations
Peers
Comparison fields: 5 of 91
- Public Health, Environmental and Occupational Health 143
- Clinical Psychology 140
- Critical Care and Intensive Care Medicine 130
- Biochemistry 94
- Pharmacology 81
Countries citing papers authored by Laura Dean
This map shows the geographic impact of Laura Dean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Dean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Dean more than expected).
Fields of papers citing papers by Laura Dean
This network shows the impact of papers produced by Laura Dean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Dean. The network helps show where Laura Dean may publish in the future.
Co-authorship network of co-authors of Laura Dean
This figure shows the co-authorship network connecting the top 25 collaborators of Laura Dean. A scholar is included among the top collaborators of Laura Dean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Dean. Laura Dean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 8 | |
| 2 | Capecitabine Therapy and DPYD Genotype | 4 |
| 3 | Cetuximab Therapy and RAS and BRAF Genotype | 4 |
| 4 | Tafenoquine Therapy and G6PD Genotype | 1 |
| 5 | Pegloticase Therapy and G6PD Genotype | 1 |
| 6 | Mercaptopurine Therapy and TPMT and NUDT15 Genotype | 1 |
| 7 | Metoprolol Therapy and CYP2D6 Genotype | 6 |
| 8 | Imipramine Therapy and CYP2D6 and CYP2C19 Genotype | 2 |
| 9 | Dabrafenib Therapy and BRAF and G6PD Genotype | 2 |
| 10 | Thioguanine Therapy and TPMT Genotype | 1 |
| 11 | 6 | |
| 12 | Warfarin Therapy and the Genotypes CYP2C9 and VKORC1 | 16 |
| 13 | Clopidogrel Therapy and CYP2C19 Genotype | 24 |
| 14 | Panitumumab Therapy and RAS and BRAF Genotype | 0 |
| 15 | Clozapine Therapy and CYP Genotype | 2 |
| 16 | Rasburicase Therapy and G6PD and CYB5R Genotype | 1 |
| 17 | 173 | |
| 18 | 108 | |
| 19 | Blood transfusions and the immune system | 2 |
| 20 | 56 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.